MNPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Monopar Therapeutics Inc (MNPR) is not a strong buy at the moment for a beginner investor with a long-term horizon. The technical indicators are bearish, there are no significant trading signals, and the company's financial performance remains weak. While an analyst has a positive outlook with a high price target, the lack of recent news, catalysts, and trading trends suggests a cautious approach. Holding or waiting for more favorable conditions is recommended.
The technical indicators for MNPR are bearish. The MACD is negative and expanding downward, the RSI is neutral at 36.674, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 54.423, with resistance at 58.73 and 63.037.
Morgan Stanley analyst Maxwell Skor initiated coverage with an Overweight rating and a $115 price target, citing the potential of ALXN1840 as a differentiated therapy for Wilson's disease.
No significant news or trading trends from insiders or hedge funds. The stock has a 30% chance of declining in the short term based on similar candlestick patterns.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$3,437,601 (up 163.56% YoY), and an EPS of -0.48 (up 29.73% YoY). Gross margin remained at 0%. The financials indicate improvement in losses but remain negative overall.
Morgan Stanley has initiated coverage with an Overweight rating and a $115 price target, citing the potential of ALXN1840 as a differentiated therapy. This is a positive outlook but lacks broader analyst consensus.
